Wednesday, March 18, 2026

PARTNER 3 Update: Long-Term Quality of Life in Low-Risk Patients

New 7-year data from the PARTNER 3 trial, presented at CRT 2026, offers critical insights for our low-risk aortic stenosis patients choosing between TAVI (Transcatheter Aortic Valve Implantation) and SAVR (Surgical Aortic Valve Replacement).

Key Clinical Takeaways:

  • Early Advantage: Patients undergoing TAVI experienced significantly faster recovery and improved health status (measured by KCCQ-OS scores) within the first 30 days compared to surgery.

  • Long-Term Equivalence: By year 7, there were no meaningful differences in quality of life or clinical outcomes between the two groups. Roughly 60% of patients in both arms remained alive and felt "well."

  • Subgroup Nuance: Interestingly, a trend favored SAVR in patients older than 74, while TAVI showed better results for those with a low LVEF ($\le 55\%$).

While the early "bounce back" of transcatheter therapy remains its hallmark, the long-term valve durability and functional stability of the Sapien 3 valve provide the "stamp of approval" for either approach in the low-risk population.


Referenced Literature

The Hidden Cardiovascular Risk in Your Pantry: Insights from MESA

Here is a fresh, professional blog article based on the latest data from the MESA study, ready for your Blogger da. While cardiologists have traditionally focused on sodium and saturated fats, a new study suggests we must shift our attention to how food is made. According to a recent analysis of the Multi-Ethnic Study of Atherosclerosis (MESA), a diet high in ultraprocessed foods (UPF) is a potent, independent driver of cardiovascular disease (CVD).

The research, published in JACC: Advances, followed over 6,500 adults and found that for every additional daily serving of UPF, there is a 5.1% relative increase in incident CVD.

What Qualifies as Ultraprocessed?

Ultraprocessed foods are industrially manufactured products engineered for high palatability and long shelf life. The MESA study specifically identified several common culprits:

 * Sugar-Sweetened Beverages: Soda and energy drinks.

 * Packaged Snacks: Chips, crackers, and mass-produced sweets.

 * Ready-to-Eat Meals: Frozen pizzas and microwave dinners.

 * Reconstituted Meat Products: Hot dogs and processed deli meats.

 * Breakfast Cereals: Most highly marketed, sugary boxed cereals.

Why Are These Foods So Dangerous?

It isn't just the calories. Researchers point to the hyperpalatable nature of these foods, which can disrupt natural satiety signaling. Furthermore, the presence of emulsifiers, artificial colors, and chemical additives may trigger inflammatory pathways and alter the gut microbiome, accelerating the development of atherosclerosis.

A Matter of Health Equity

One of the most striking findings of the trial was the disproportionate impact on Black Americans. The study noted that a 10% increase in UPF intake resulted in a 12.3% higher CVD risk for Black participants, compared to 7.9% in non-Black participants. This suggests that structural factors—such as limited access to fresh produce and targeted marketing—play a major role in these outcomes.

The Bottom Line for Patients

The transition from ultraprocessed to minimally processed foods (like whole grains, fresh fruits, and lean proteins) is one of the most effective "prescriptions" for heart health.

Clinical Tip: If a food's ingredient list looks like a chemistry textbook, it’s likely ultraprocessed. Aim to shop the perimeter of the grocery store where whole foods are typically located.


Journal Reference

Haidar A, Rikhi R, Watson KE, et al. Association between ultraprocessed food consumption and cardiovascular disease risk: MESA (Multiethnic Study of Atherosclerosis). JACC Adv. 2026;5(3):102516.


The LAAO Paradox: Lessons from the CLOSURE-AF Trial

For years, Left Atrial Appendage Occlusion (LAAO) has been the primary alternative for atrial fibrillation (AF) patients who cannot tolerate long-term anticoagulation. However, new data from the CLOSURE-AF trial, recently published in the New England Journal of Medicine, is shifting the clinical narrative.

In a surprising result, the study found that for patients at high risk for both stroke and bleeding, standard medical care (predominantly DOACs) was actually superior to the LAAO procedure.

Key Clinical Findings

The study followed 912 high-risk patients over a median of three years, revealing several critical insights:

 * Failure of Noninferiority: LAAO did not meet the statistical criteria to be considered "just as good" as medical therapy.

 * Higher Event Rates: The LAAO group saw 16.83 events per 100 person-years (composite of stroke, embolism, major bleeding, and CV death) compared to 13.27 in the medical care group.

 * Periprocedural Risk: A significant portion of the bleeding events in the LAAO arm occurred during or immediately after the procedure itself.

Why the Shift?

While some experts argue that next-generation devices and increased operator experience might yield different results today, the trial highlights that modern medical therapy is a formidable "gold standard." For high-risk populations, the immediate surgical risks must be more carefully weighed against the long-term efficacy of DOACs.

The Bottom Line: While LAAO remains a vital tool, CLOSURE-AF serves as a reminder that medical management is often the safer, more effective route for our most vulnerable patients.

Journal Reference

Landmesser U, et al. Left Atrial Appendage Closure in Patients with Atrial Fibrillation at High Risk of Stroke and Bleeding. New England Journal of Medicine. 2026.

The Surveillance Gap: Why Aortic Stenosis Monitoring is Falling Short

In the management of Aortic Stenosis (AS), we often focus on the "when" and "how" of intervention. However, new research highlights a more fundamental challenge: the "if" of consistent monitoring. A recent large-scale study published in Circulation: Population Health and Outcomes reveals a significant gap between clinical guidelines and real-world echocardiographic surveillance.

The data, which followed over 20,000 patients, suggests that many of our highest-risk patients are not receiving recommended follow-up scans, directly impacting survival rates and the timing of Aortic Valve Replacement (AVR).

The Surveillance Paradox

The study found a counterintuitive trend: as the severity of the disease increases, adherence to monitoring guidelines actually decreases.

 * Severe AS: Only 49% of patients received an echo within the recommended 6–12 month window.

 * Mild AS: Conversely, 74% of patients were monitored according to the 3–5 year guideline.

 * The Survival Link: Patients who remained guideline-concordant had significantly lower mortality rates (28.8%) compared to those who were not (42.2%).

Identifying Barriers to Care

Why are high-risk patients falling through the cracks? Several "real-world" factors contribute to this oversight:

 * Symptom Masking: Because AS is often asymptomatic until a critical stage, patients may not feel the urgency of a "routine" scan.

 * Fragmented Follow-up: As patients age, care often transitions between multiple providers, leading to missed reminders.

 * The Specialist Factor: Patients managed by a cardiologist were much more likely to stay updated on their surveillance than those managed solely by primary care.

Future Solutions: AI and System Alerts

To bridge this gap, the medical community is looking toward AI-driven solutions. Natural language processing (NLP) can be used to interpret echo reports and trigger automated provider alerts when a patient is due for follow-up. Programs like the AHA’s Target: Aortic Stenosis are also working to standardize care from diagnosis to intervention.

Clinical Perspective

For providers, the takeaway is clear: active surveillance is a mortality-reducing intervention. For patients, a "routine" echo is the most vital tool we have to ensure we intervene at the "sweet spot" of disease progression.

The Bottom Line: We must move toward a proactive, system-level approach to ensure no patient with Aortic Stenosis is "lost to follow-up."

Reference

Fitzpatrick JK, Go AS, Bauer M, et al. Association of guideline-concordant echocardiographic surveillance with mortality and aortic valve replacement in US adults with aortic stenosis. Circ Popul Health Outcomes. 2026;19:e012822.

Monday, March 16, 2026

Skip the Antiplatelet: OAC Alone Wins for AF Patients With Stable CAD

 A large meta-analysis finds that dropping antiplatelet therapy cuts cardiovascular mortality and bleeding — without raising ischemic risk.

March 2026  ·  Based on findings published in JACC
31%
lower cardiovascular mortality with OAC alone
54%
lower major bleeding risk
~6,000
patients across 6 randomized trials

For patients with atrial fibrillation (AF) who also have stable coronary artery disease (CAD), a long-debated clinical question may now have a definitive answer: oral anticoagulation alone is better than pairing it with an antiplatelet agent.

A new meta-analysis pooling data from six randomized controlled trials — including ADAPT AF-DES, AFIRE, OAC-ALONE, and others — found that OAC monotherapy delivered meaningful reductions in both cardiovascular death and major bleeding, with no increase in heart attacks, strokes, or stent thrombosis.

"The precision of the estimate is so good now that basically there is only harm in using two agents at the same time."

— Marco Valgimigli, MD, PhD, Cardiocentro Ticino Institute

The analysis, published in JACC, covered nearly 6,000 patients followed for up to 30 months. Compared with those on combination therapy, patients on OAC alone had a 31% lower risk of cardiovascular death and a 54% lower risk of major bleeding. Importantly, rates of major adverse cardiovascular events (MACE), MI, and stroke were statistically similar between groups — meaning the bleeding benefit came with no ischemic tradeoff.

In practical terms, the authors estimated that at one year, OAC monotherapy would prevent roughly 6 cardiovascular deaths and 15 major bleeding episodes per 1,000 patients, compared with combination therapy.

Co-author Duk-Woo Park, MD, of Asan Medical Center (Seoul) called the mortality finding the most notable result. Many clinicians have continued dual therapy out of concern about late ischemic events — but this data now challenges that rationale directly.

The findings apply specifically to patients who are beyond the acute post-PCI or post-ACS phase. As Park emphasized, the takeaway is not that antiplatelets are never needed — rather, once a patient has stabilized and is on long-term OAC, simplifying to monotherapy appears both safer and potentially more effective overall.

Valgimigli believes the evidence is now strong enough to influence clinical guidelines, calling for a shift to OAC monotherapy "as early as possible" — a recommendation the ongoing MATRIX-2 trial is expected to refine further.

Source: Gargiulo G, Piccolo R, Park D-W, et al. Anticoagulation alone or with antiaggregation in patients with coronary artery disease: meta-analysis of randomized trials. JACC. 2026; Epub ahead of print.

Study settles the apixaban vs. rivaroxaban debate for blood clots

New trial data show apixaban cuts clinically relevant bleeding by more than half compared to rivaroxaban — without any loss of clot-prevention benefit.

For years, clinicians treating venous thromboembolism (VTE) had little evidence to choose between the two most popular blood thinners. The COBRRA trial, published this month in the New England Journal of Medicine, changes that.

Among 2,760 patients treated for acute VTE, those taking apixaban experienced clinically relevant bleeding at roughly half the rate of those on rivaroxaban (3.3% vs. 7.1%). Major bleeding was even more striking — 0.4% with apixaban versus 2.4% with rivaroxaban. Crucially, rates of recurrent blood clots were identical between the two groups.

Bleeding reduction

54%

Patients enrolled

2,760

Clot recurrence difference

None

Researchers believe the difference stems largely from dosing: rivaroxaban's loading phase — twice-daily high doses for 21 days — appears to drive excess bleeding without providing additional protection against clots. Apixaban's loading phase lasts only 7 days.

An accompanying editorial concluded that for most VTE patients, the choice of anticoagulant is "no longer a toss-up." Rivaroxaban may still suit patients who prefer a once-daily regimen, but the safety edge for apixaban is now hard to ignore.

Source: Castellucci et al., NEJM, March 12/19, 2026 · COBRRA trial

Sunday, March 15, 2026

2026 ACC/AHA Dyslipidemia Guidelines: Lower LDL, Starting Earlier in Life

 What's new at a glance

The updated guidelines replace the longstanding Pooled Cohort Equations (PCE) with the PREVENT risk calculator, reinstate specific LDL cholesterol targets absent since 2013, and emphasize 30-year lifetime ASCVD risk rather than 10-year snapshots alone. Several newly FDA-approved agents — bempedoic acid, inclisiran, and evinacumab — are incorporated into the treatment landscape.

The case for treating earlier

A central theme is reducing lifelong exposure to atherogenic lipoproteins by intervening earlier. Once arterial plaque develops, it cannot be reversed — making prevention before disease onset the priority.

Statin therapy is now recommended earlier for:

  • All adults with heterozygous familial hypercholesterolemia (FH)
  • Adults ≤30 years old with LDL ≥ 160 mg/dL
  • Those with a strong family history of ASCVD
  • Those with high 30-year ASCVD risk on the PREVENT calculator
The ideal LDL cholesterol goal for primary prevention is ≤ 100 mg/dL, supported by lifestyle optimization and pharmacotherapy when needed.

Primary prevention: risk-stratified targets

The PREVENT calculator defines four risk tiers, each with clear guidance:

  • Low risk (<3% 10-year) with LDL 160–189 mg/dL or 30-year risk ≥10%: moderate-intensity statin is reasonable (Class 2a)
  • Borderline risk (3–<5%): LDL target <100 mg/dL; moderate-intensity statin based on shared decision-making (Class 2a)
  • Intermediate risk (5–<10%): moderate- or high-intensity statin per clinical judgment (Class 1)
  • High risk (>10% 10-year): LDL target <70 mg/dL; high-intensity statin for ≥50% LDL reduction (Class 1)

Recommending treatment even for borderline-risk patients with LDL near 160 mg/dL represents a significant shift from prior guidelines.

Lipoprotein(a) and coronary artery calcium: stronger roles

Lp(a) measurement is now a Class 1 recommendation — once in every adult's lifetime. An elevated level (≥ 50 mg/dL) triggers intensified LDL lowering and broader risk factor management.

Coronary artery calcium (CAC) scoring serves as the premier "tiebreaker" when treatment decisions are uncertain:

  • CAC = 0: Consider deferring therapy
  • CAC 1–999 AU: Treat to LDL <70 mg/dL and non-HDL <100 mg/dL (Class 1)
  • CAC ≥ 1,000 AU: Target LDL <55 mg/dL with ≥50% LDL reduction (Class 1)

ApoB testing and the CPR model

Apolipoprotein B (apoB) testing now has a clear pathway (Class 2a) for further risk stratification once LDL and non-HDL goals are met, particularly in patients with elevated triglycerides, diabetes, or cardiovascular-kidney-metabolic (CKM) syndrome.

The guidelines encourage a "CPR" framework: Calculate 10- and 30-year risk, Personalize using risk enhancers and biomarkers, then Reclassify and Reassess over time.

Secondary prevention: tighter targets for very-high-risk patients

For patients with established ASCVD at very high risk — two or more major ASCVD events, or one event plus two additional high-risk conditions — goals are now:

  • LDL <55 mg/dL and non-HDL <85 mg/dL

To achieve these targets, ezetimibe and/or a PCSK9 inhibitor should be added to maximally tolerated statin therapy (Class 2a). Inclisiran is a reasonable alternative for patients who cannot tolerate or prefer less-frequent dosing (Class 2a).

Risk enhancers and special populations

Multiple risk enhancers can influence treatment in borderline or intermediate-risk patients, including family history, high-risk ancestry (South Asian, Filipino), elevated high-sensitivity CRP, elevated triglycerides, and presence of inflammatory diseases or CKM syndrome.

Additional guidance covers:

  • Chronic kidney disease (stages 3–4): LDL <55 mg/dL target — Class 1 recommendation
  • HIV patients (ages 40–75) on stable antiretroviral therapy: statins recommended (Class 1)
  • Diabetes without ASCVD: statin therapy recommended (Class 1)
  • Hypertriglyceridemia: lifestyle-first — ≥5% weight loss and ≥150 min/week moderate exercise
  • Pregnancy and lactation: nuanced shared discussion replacing a blanket statin stop; dietician referral encouraged

Bottom line: The 2026 ACC/AHA guidelines return LDL targets, extend the treatment window to younger adults, elevate Lp(a) and CAC scoring as key decision-making tools, and align US recommendations more closely with European standards. The overarching message: lower cholesterol, for longer, starting sooner.

Thursday, March 5, 2026

CRT 2026 March 7-10, 2026 in DC

The Cardiovascular Research Technologies (CRT) conference kicks off March in DC. Worth noting: this year has 30+ late-breaking clinical trials (LBCTs) across 4 days — more than usual. Going to be a lot to cover.

Saturday — Coronary Day

Two LBCT sessions to pay attention to:

Coronary I — The big one here is the SUGAR trial (5-year follow-up): polymer-free amphilimus stent vs. permanent-polymer zotarolimus stent in diabetic patients. Also AGENT IDE (3-year data) on a drug-coated balloon for in-stent restenosis — good follow-up topic for my stent post.

Coronary II — The X1-ACCURACY study is interesting: AI-assisted single-view angiographic FFR vs. invasive hyperemic FFR. If AI can replace invasive measurement, that's a big deal. Also a meta-analysis on angiography, imaging, and physiology to guide coronary revascularization — could tie into my piece on diagnostic approaches.

Sunday — Coronary III & Cardiogenic Shock

The clopidogrel vs. aspirin monotherapy study is one to watch — looking at post-PCI patients (beyond 12 months) at high CV risk. Antiplatelet therapy debates are always popular with readers.

Also: DOBERMANN-D trial — low-dose dobutamine infusion effect on NT-proBNP in acute MI patients at risk of cardiogenic shock. Niche but important for the critical care crowd.

Monday — Structural Heart + Biden Keynote

Don't miss the Women in Cardiology session — always good material.

Featured Clinical Science has a SELUTION trial substudy on how operator experience affects sirolimus-eluting balloon outcomes in de novo coronary lesions. Learning curve data — worth a mention.

LBCTs Monday are structural-heavy: tirzepatide (Zepbound) data on subclinical leaflet thrombosis and paravalvular leak after TAVI in obese patients. Also real-world reintervention rates in low-risk Medicare TAVI patients — good for the health policy angle.

Evening keynote: President Biden (46th POTUS) speaks at 8 PM. Get there early — it'll be packed.

Tuesday — Endovascular

The CARPOOL study is the highlight: radial-to-peripheral (R2P) vs. femoral access in PAD revascularization. Access site debate in peripheral — my readers will like this.

Also: standard vs. enhanced radiation protection devices in peripheral cases, and a CREST-2 trial update from the chair. Follow up on what's new there.